Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination. (Q30371445)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination. |
scientific article |
Statements
1 reference
Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination. (English)
1 reference
1 reference
Paul Gillard
1 reference
José-María Baldó
1 reference
Maria Victoria Planelles-Catarino
1 reference
María Garcés-Sánchez
1 reference
Isabel Ubeda
1 reference
Angels Jubert-Rosich
1 reference
Josep Marès
1 reference
Pilar Garcia-Corbeira
1 reference
Philippe Moris
1 reference
Maurice Teko
1 reference
Carline Vanden Abeele
1 reference
1 reference
1 reference
Identifiers
1 reference